Guerbet releases Xenetix agent:
This article was originally published in Clinica
Executive Summary
Guerbet's new nonionic contrast agent - XENETIX - is intended for angiographic and urographic applications. It has been tested in clinical trials involving 2000 patients and has a high degree of biological inertness, thus minimising interactions with circulating proteins and cell membranes.